Why Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Up 11.86%
As of Friday, November 06, Kalaris Therapeutics, Inc.’s KLRS share price has surged by 11.86%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Michael Rose
Jenna Brashear
Jenna Brashear
Rosalio Madrigal
| Share Statistics | KLRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $29.8 | $203.5 | 14% |
|
| Shares Out (Mil) | 23.8 | 55.2 | 33% |
|
| Institutional Ownership | 68.0% | 93.3% | 42% |
|
| Float (Mil) | 5.9 | 40.4 | 14% |
|
| Beta | na | 1.05 | na |
|
| Avg Daily Volume (000s) | 100 | 569 | 36% |
|
| Price Change (52-week) |
(81.3%) | 38.8% | 9% |
|
| Growth | KLRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.7%) | na |
|
| EPS (5yr) | na | 15.4% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.513) | ($1.914) | ($2.061) | |
| Month Ago EPS | ($0.543) | ($2.001) | ($1.653) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.544) | ($2.008) | ($1.659) | |
| Year/Year Chg | 10.8% | (32.7%) | (18.6%) | |
| Financials | KLRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($43) | ($44) | 17% |
|
| EPS (TTM) | ($1.912) | ($1.400) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($40) | ($35) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $-0 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | ($49) | $142 | 1% |
|
| Valuation | KLRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.63 | 1.96 | 16% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KLRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (51.0%) | (47.0%) | 11% |
|
| ROE | (97.2%) | (51.8%) | 9% |
|
| Liabilities to Assets | 46.7% | 29.6% | 38% |
|
| F-Score | 3 | 3 | 18% |
|
Kalaris Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors